The therapeutic landscape for lymphoma is undergoing a transformative shift, moving away from traditional cytotoxic intensification toward more targeted, mechanism-driven strategi ...

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...

Lymphoma care still leaves gaps—research aims for higher cure rates, longer remission, and fewer toxicities across B-, T-cell and Hodgkin.

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in ...

While rare, secondary cancers after CAR T-cell therapy have been reported, leading the FDA to mandate boxed warnings on all approved therapies. In a first, targeted therapy was used to treat a T-cell ...

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

The TERZO study evaluates Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma, lacking a standard treatment. The trial compares Copiktra with Gemzar or Bendeka, focusing on ...

Epigenetic therapies are offering a more targeted way to treat some lymphomas by changing how genes are turned on or off ...